Literature DB >> 21989990

Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells.

Fabio Morandi1, Elisa Ferretti, Roberta Castriconi, Alessandra Dondero, Andrea Petretto, Cristina Bottino, Vito Pistoia.   

Abstract

Soluble HLA-G (sHLA-G) inhibits natural killer (NK) cell functions. Here, we investigated sHLA-G-mediated modulation of (1) chemokine receptor and NK receptor expression and function and (2) cytokine and chemokine secretion in CD56bright and CD56dim NK cells. sHLA-G-treated or untreated peripheral blood (PB) and tonsil NK cells were analyzed for chemokine receptor and NK receptor expression by flow cytometry. sHLA-G down-modulated (1) CXCR3 on PB and tonsil CD56bright and CD56dim, (2) CCR2 on PB and tonsil CD56bright, (3) CX3CR1 on PB CD56dim, (4) CXCR5 on tonsil CD56dim, and (5) CD94/NKG2A on PB and tonsil CD56brigh) and CD56dim NK cells. Such sHLA-G-mediated down-modulations were reverted by adding anti-HLA-G or anti-ILT2 mAbs. sHLA-G inhibited chemotaxis of (1) PB NK cells toward CXCL10, CXCL11, and CX3CL1 and (2) PB CD56bright NK cells toward CCL2 and CXCL10. IFN-γ secretion induced by NKp46 engagement was inhibited by NKG2A engagement in untreated but not in sHLA-G-treated NK cells. sHLA-G up-regulated secretion of (1) CCL22 in CD56bright and CD56dim and (2) CCL2, CCL8, and CXCL2-CXCL3 in CD56dim PB NK cells. Signal transduction experiments showed sHLA-G-mediated down-modulation of Stat5 phosphorylation in PB NK cells. In conclusion, our data delineated novel mechanisms of sHLA-G-mediated inhibition of NK-cell functions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989990     DOI: 10.1182/blood-2011-05-352393

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes.

Authors:  Jie Yan; Matija Hedl; Clara Abraham
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

2.  Soluble HLA-G modulates miRNA-210 and miRNA-451 expression in activated CD4+ T lymphocytes.

Authors:  Fabio Morandi; Vito Pistoia
Journal:  Int Immunol       Date:  2012-12-05       Impact factor: 4.823

3.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

Review 4.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

5.  Recognition of the Major Histocompatibility Complex (MHC) Class Ib Molecule H2-Q10 by the Natural Killer Cell Receptor Ly49C.

Authors:  Lucy C Sullivan; Richard Berry; Natasha Sosnin; Jacqueline M L Widjaja; Felix A Deuss; Gautham R Balaji; Nicole L LaGruta; Michiko Mirams; Joseph A Trapani; Jamie Rossjohn; Andrew G Brooks; Daniel M Andrews
Journal:  J Biol Chem       Date:  2016-07-06       Impact factor: 5.157

Review 6.  Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiaoyin Bu; Jinman Zhong; Weiru Li; Shengchun Cai; Ya Gao; Baohong Ping
Journal:  Ann Hematol       Date:  2021-03-11       Impact factor: 3.673

7.  Downregulation of key early events in the mobilization of antigen-bearing dendritic cells by leukocyte immunoglobulin-like Receptor B4 in a mouse model of allergic pulmonary inflammation.

Authors:  Laura B Fanning; Carolyn C Buckley; Wei Xing; Rebecca G Breslow; Howard R Katz
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

Review 8.  Targeting natural killer cells to enhance vaccine responses.

Authors:  Andrew Cox; Hilal Cevik; H Alex Feldman; Laura M Canaday; Nora Lakes; Stephen N Waggoner
Journal:  Trends Pharmacol Sci       Date:  2021-07-23       Impact factor: 17.638

Review 9.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.